Reverse transcriptase mutant as well as preparation method and application thereof

Site-directed mutation screening in the structural characteristics and key amino acid sites of wild-type MMLV reverse transcriptase was obtained, which solved the problem of long reverse transcription reaction time in the prior art, and realized the reverse transcriptase mutant. The synthesis of cDNA within 5 minutes shortens the entire process time of RT-qPCR and improves the application efficiency in the field of molecular diagnosis.

CN119082074APending Publication Date: 2024-12-06GUANGZHOU WONDFO BIOTECH
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411212184.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing reverse transcriptase has a long reaction time under high temperature conditions, which is difficult to meet the demand for rapid synthesis of cDNA in the field of molecular diagnosis.

Method used

By rationally designing the structural characteristics and key amino acid sites of wild-type MMLV reverse transcriptase, site-directed mutation screening was performed to obtain reverse transcriptase mutants, shortening the reverse transcription reaction time to 5 minutes, which is suitable for one-step RT-qPCR.

Benefits of technology

It significantly shortens the entire process time of RT-qPCR, improves the efficiency of instrument use, and has a wide range of application scenarios in the field of molecular diagnosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082074A_ABST
    Figure CN119082074A_ABST
Patent Text Reader

Abstract

The invention discloses a reverse transcriptase mutant as well as a preparation method and application thereof. On the basis of a wild type amino acid sequence SEQ ID NO.1, the reverse transcriptase mutant comprises any one or a combination of at least two of the following site mutations: D524N, E123K, K259D or Q466R. A series of efficient reverse transcriptase is obtained through site-directed mutagenesis screening, and compared with 15-30 min of wild type MMLV reverse transcriptase, the time for synthesizing cDNA through the reverse transcriptase mutant is only 5 min, the whole process time of RT-qPCR is further shortened, the use efficiency of an instrument is improved, development of RT-qPCR products through a further method is promoted, and the application prospect is wide. The method has a wide application scene in the field of molecular diagnosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology and relates to a reverse transcriptase mutant and a preparation method and application thereof. Background Art

[0002] Reverse transcriptase (RT) is an enzyme responsible for RNA viral genome replication, with RNA and DNA dependent DNA polymerase (the ability to synthesize cDNA using RNA or DNA as template) and RNase H activity (the activity of degrading RNA chain in RNA / DNA hybrid chain). At present, most reverse transcriptases in molecular biology are derived from Moloney murine leukemia virus (MMLV), which is a monomeric enzyme with a molecular weight of 75kDa, an optimal reaction temperature of about 37°C, and a reaction time of generally 15-30min.

[0003] RT-qPCR is one of the most important technologies in the field of molecular diagnosis. The first step is to reverse transcribe the RNA template to generate cDNA, and then use the synthesized cDNA as a template for real-time fluorescence PCR reaction. Shortening the reverse transcription reaction time can also promote the development of fast RT-qPCR products and increase the turnover rate of the instrument.

[0004] CN112795549A discloses a reverse transcriptase mutant. Specifically, this invention constructs a reverse transcriptase (M-MLV) mutant library, and through step-by-step screening, finally screens out a mutant (reverse transcriptase mutant Mu_15) with improved thermal stability and higher amplification efficiency. Under high temperature conditions (58°C), compared with the wild type, the reverse transcription efficiency of the reverse transcriptase mutant Mu_15 of this invention is increased by 39.67 times, but the reaction time is longer.

[0005] Therefore, in the field of molecular diagnosis, there is an urgent need for a reverse transcriptase that can efficiently and quickly synthesize cDNA. Summary of the invention

[0006] In view of the deficiencies in the prior art and actual needs, the present invention provides a reverse transcriptase mutant and a preparation method and application thereof. Based on the wild-type MMLV reverse transcriptase, the present invention performs rational design according to its structural characteristics and key amino acid sites, screens and obtains new reverse transcriptases through site-directed mutagenesis, combines the properties of mutants with different excellent properties, and obtains a series of efficient and rapid reverse transcriptases. The reverse transcription reaction time can be shortened to 5 minutes, which is more suitable for one-step RT-qPCR.

[0007] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0008] In a first aspect, the present invention provides a reverse transcriptase mutant, wherein the reverse transcriptase mutant has any one or a combination of at least two of the following site mutations based on the wild-type amino acid sequence SEQ ID NO.1: D524N, E123K, K259D or Q466R.

[0009] According to the existing structural research of wild-type MMLV reverse transcriptase, the present invention performs rational design through its structural characteristics and key amino acid sites, and obtains a series of more efficient reverse transcriptases through site-directed mutagenesis screening. Compared with 15-30 minutes of wild-type MMLV reverse transcriptase, the cDNA synthesis time of the reverse transcriptase mutant of the present invention is only 5 minutes, which further shortens the whole process time of RT-qPCR, increases the use efficiency of the instrument, promotes the development of one-step RT-qPCR products, and has a wide range of application scenarios in the field of molecular diagnosis.

[0010] The MMLV reverse transcriptase mutant provided by the present invention is obtained by performing mutations in amino acid sites based on the amino acid sequence (NCBI, accession number NP_955591) of the wild-type MMLV reverse transcriptase with a total length of 671 amino acids, namely, SEQ ID NO.1.

[0011] SEQ ID NO.1:

[0012] .

[0013] In a second aspect, the present invention provides a nucleic acid molecule comprising a coding sequence of the reverse transcriptase mutant described in the first aspect.

[0014] In a third aspect, the present invention provides a recombinant vector comprising the nucleic acid molecule described in the second aspect.

[0015] In a fourth aspect, the present invention provides a recombinant cell, wherein the recombinant cell contains the nucleic acid molecule described in the second aspect and / or the recombinant vector described in the third aspect.

[0016] In a fifth aspect, the present invention provides a kit comprising any one or a combination of at least two of the murine leukemia virus reverse transcriptase mutant described in the first aspect, the nucleic acid molecule described in the second aspect, the recombinant vector described in the third aspect, or the recombinant cell described in the fourth aspect.

[0017] In a sixth aspect, the present invention provides a method for preparing the reverse transcriptase mutant according to the first aspect, the method comprising the following steps:

[0018] (1) inserting the nucleic acid sequence of reverse transcriptase SEQ ID NO.2 into an expression vector to obtain a wild-type recombinant plasmid MMLVwt, and using the recombinant plasmid as a template, performing site-directed mutagenesis on any one of the 524th, 123rd, 259th, or 466th sites of the reverse transcriptase, or a combination of at least two of them;

[0019] (2) The mutant plasmid obtained in step (1) is transformed into a host bacterium, cultured and purified to obtain the reverse transcriptase mutant.

[0020] SEQ ID NO.2:

[0021]

[0022] Preferably, the expression vector comprises pET28a(+).

[0023] Preferably, the host bacteria include Escherichia coli, Pichia pastoris or Bacillus subtilis.

[0024] In a seventh aspect, the present invention provides use of the reverse transcriptase mutant described in the first aspect in a reverse transcription reaction.

[0025] Preferably, the reverse transcription reaction includes any one of RT-PCR, RT-qPCR or RT-LAMP.

[0026] Compared with the prior art, the present invention has the following beneficial effects:

[0027] According to the existing structural research of wild-type MMLV reverse transcriptase, the present invention performs rational design through its structural characteristics and key amino acid sites, and obtains a series of more efficient reverse transcriptases through site-directed mutagenesis screening. Compared with 15-30 minutes of wild-type MMLV reverse transcriptase, the cDNA synthesis time of the reverse transcriptase mutant of the present invention is only 5 minutes, which further shortens the whole process time of RT-qPCR, increases the use efficiency of the instrument, promotes the development of one-step RT-qPCR products, and has a wide range of application scenarios in the field of molecular diagnosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 Schematic diagram for bridging PCR primer design;

[0029] Figure 2 The amplification results of mutant reverse transcriptase under different reverse transcription conditions;

[0030] Figure 3 This is a staining diagram of the highly efficient and rapid reverse transcriptase Mut D after purification;

[0031] Figure 4 This is a graph showing the results of one-step RT-qPCR amplification. DETAILED DESCRIPTION

[0032] To further illustrate the technical means and effects of the present invention, the present invention is further described below in conjunction with the embodiments and drawings. It should be understood that the specific implementation methods described herein are only used to explain the present invention, rather than to limit the present invention.

[0033] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0034] Example 1

[0035] Nucleotide sequences of MMLV reverse transcriptase mutants and their construction.

[0036] The recombinant vector MMLVwt of the wild-type MMLV reverse transcriptase was obtained by introducing the nucleic acid sequence encoding the MMLV reverse transcriptase (NCBI, accession number NP_955591), i.e., the sequence SEQ ID NO.2, into the expression vector pET-28a(+) by synthesis, and introducing EcoRI and NotI restriction endonuclease sites at both ends, respectively. The target sequence of the reverse transcriptase mutant was obtained by bridge PCR, Figure 1 Schematic diagram of the design for its introduction, where the point mutation region is located Figure 1 The obtained target gene fragments were connected to the expression vector through restriction enzyme cutting sites to obtain MMLV reverse transcriptase mutant recombinant plasmids. The primer sequences of each mutation site are shown in Table 1, and the names of each mutant and the mutation site information are shown in Table 2.

[0037] Table 1

[0038]

[0039] Table 2

[0040]

[0041]

[0042] Example 2

[0043] Expression of MMLV reverse transcriptase and screening of mutants.

[0044] (1) Low-level expression of reverse transcriptase

[0045] The wild-type expression vector MMLVwt and the mutant expression vector MMLV Mut obtained in Example 1 were transformed into competent E. coli cells and cultured overnight at 37°C until OD 600 =0.6, add the inducer IPTG at a concentration of 0.4 mM, and continue to culture at 25°C for 8 h. Collect the cells by centrifugation, add lysozyme for ultrasonic disruption, and obtain a crude extract of reverse transcriptase.

[0046] (2) Screening of efficient and rapid reverse transcriptase

[0047] Human total RNA was used as a template and amplified by two-step RT-PCR. The reaction system of reverse transcription reaction RT is shown in Table 3, and the qPCR reaction system is shown in Table 4. The Rnase P primer sequences in qPCR are F: ATGGCGGTGTTTGCAGATTT (SEQID NO.11) and R: GAGCGGCTGTCTCCACAAGT (SEQ ID NO.12), and the probe sequence of qPCR is FAM-TTCTGACCTGAAGGCTCTGCGCG-BHQ (SEQ ID NO.13). The wild-type reverse transcriptase MMLVwt was used as the control group, and its reverse transcription reaction temperature was 37°C and the reverse transcription reaction time was 10min. The reverse transcription reaction temperature of the mutant was 50°C, and the reverse transcription reaction time was set to 5min and 10min, respectively. Amplification was performed by two-step RT-PCR. The smaller the CT value of qPCR, the higher the efficiency of the reverse transcription reaction. The results are shown in Figure 2 As shown, at 10 min, compared with the wild-type reverse transcriptase in the control group, the performance of each mutant reverse transcriptase was improved, among which the mutant Mut D had the highest reverse transcription reaction efficiency.

[0048] Table 3

[0049] Reagents Volume (μL) 5×buffer 4 dNTPs (10mmol / L) 1 Oligo(dT)23VN(50μM) 1 RNaseInhibitor (40U / μL) 1 RT (200 U / μL) 1 RNA template (1 μg / μL) 1 <![CDATA[DEPCH2O]]> To a total volume of 20

[0050] Table 4

[0051] Reagents Volume (μL) 2×buffer 10 Forward primer (10 μM) 0.4 Reverse primer (10 μM) 0.4 TaqHS (5U / μL) 0.4 RNaseP probe 0.8 cDNA template 2 <![CDATA[DEPCH2O]]> To a total volume of 20

[0052] Example 3

[0053] Preparation of MMLV efficient and rapid reverse transcriptase mutants.

[0054] Take the strain (25% glycerol) stored at -80℃, streak with an inoculation loop, pick a single colony, and culture overnight at 37℃, 220rpm / min until OD 600=0.6, add the inducer IPTG at a concentration of 0.4mM, and continue to culture at 25℃ for 8h. Collect the bacteria, centrifuge at 7500×g, 4℃ for 15min, and discard the supernatant. According to the volume ratio of bacterial liquid to lysis solution (50mM Tris-HCl, 5mMImid, 300mM NaCl, 5% Glycerol, pH8.0, 1mM PMSF, PMSF is added immediately after use) of 10:1, resuspend the bacteria, and ultrasonically break them on ice. The ultrasonic conditions are 4℃, 5s / 5s, and 25% power until the suspension is uniform and transparent. After centrifugation at 7500×g, 4℃ for 30min, take 20μL of supernatant and 20μL of precipitate after ultrasonication, respectively, and cook them for SDS-PAGE detection. The remaining supernatant was purified by affinity chromatography, wherein the column equilibrium solution A was 50 mM Tris-HCl, 5 mM Imid, 300 mM NaCl, 5% Glycerol, pH 8.0. After the sample was loaded, different concentrations of imidazole were used for gradient elution, wherein the imidazole concentration was 100 mM. The results of the reverse transcription mutant MutD after affinity chromatography purification are shown in FIG. Figure 3 The fractions with a purity of more than 90% of the target protein were collected, dialyzed, and stored in aliquots at -20°C using a storage solution (10 mM Tris-HCl, 300 mM KCl, 0.1 mM EDTA, 1 mM DTT, 0.1% TritonX-100, 10 mg / mL BSA, 50% Glycerol, pH 7.4).

[0055] Example 4

[0056] Application of MMLV efficient and rapid reverse transcriptase mutants in one-step RT-qPCR.

[0057] The highly efficient and rapid reverse transcriptase mutants Mut C and Mut D obtained in Example 3 were subjected to one-step RT-qPCR reaction detection, respectively, and the reaction system is shown in Table 5. The detection targets are influenza A and B viruses and the internal reference gene RNase P, and the fluorescent groups of the fluorescent probes at the 5' end are VIC, ROX and FAM, respectively. The reaction procedure is reverse transcription at 50°C / 5min, reverse transcriptase inactivation and pre-denaturation at 95°C / 2min, denaturation at 95°C / 10s, annealing, extension and fluorescence detection at 60°C / 30s, wherein the number of denaturation and extension cycles is 40, and the D524N mutant Mut C reverse transcriptase is used as the control group. The detection results are shown in Figure 4As shown in Table 6, the control group did not achieve detection of VIC and ROX channels, i.e., influenza A and influenza B targets, while the MutD reverse transcriptase could achieve full detection of the three targets, and the Ct value was lower than that of the control group, indicating that the performance of the combined mutant Mut D reverse transcriptase of the present invention is better than that of the Mut C reverse transcriptase, that is, the present invention greatly shortens the reaction time of RT-qPCR while ensuring the activity of the reverse transcriptase.

[0058] Table 5

[0059] Reagents Volume (μL) 2×buffer 12.5 FluA-F (10 μM) 0.4 FluA-R (10 μM) 0.4 FluB-F (10 μM) 0.4 FluB-R (10 μM) 0.4 RNase P-F (10 μM) 0.4 RNaseP-R (10μM) 0.4 FluA-Probe (10 μM) 0.8 FluB-Probe (10 μM) 0.8 RNaseP-Probe (10μM) 0.8 TaqHS (5U / μL) 0.4 Reverse transcriptase RT (200U / μL) 0.4 sample 5 <![CDATA[DEPCH2O]]> To total volume 25

[0060] Table 6

[0061]

[0062] It can be seen from Table 6 that the mutant MMLV reverse transcriptase of the present invention significantly shortens the detection time and the entire process time of RT-qPCR.

[0063] In summary, based on the existing structural research of wild-type MMLV reverse transcriptase, the present invention is rationally designed through its structural characteristics and key amino acid sites, and a series of more efficient reverse transcriptases are obtained through site-directed mutagenesis screening. Compared with 15-30 minutes of wild-type MMLV reverse transcriptase, the cDNA synthesis time of the reverse transcriptase mutant of the present invention is only 5 minutes, which further shortens the whole process time of RT-qPCR, increases the efficiency of instrument use, promotes the development of one-step RT-qPCR products, and has a wide range of application scenarios in the field of molecular diagnosis.

[0064] The applicant declares that the present invention illustrates the detailed method of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned detailed method, that is, it does not mean that the present invention must rely on the above-mentioned detailed method to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

Claims

1. A reverse transcriptase mutant, characterized in that: The reverse transcriptase mutant is based on the wild-type amino acid sequence SEQ ID NO.1 and undergoes any one or a combination of at least two of the following site mutations: D524N, E123K, K259D or Q466R.

2. A nucleic acid molecule, characterized in that The nucleic acid molecule contains the coding sequence of the reverse transcriptase mutant according to claim 1.

3. A recombinant vector, characterized in that: The recombinant vector contains the nucleic acid molecule according to claim 2.

4. A recombinant cell, characterized in that The recombinant cell contains the nucleic acid molecule according to claim 2 and / or the recombinant vector according to claim 3.

5. A kit, characterized in that: The kit contains any one of the murine leukemia virus reverse transcriptase mutant according to claim 1, the nucleic acid molecule according to claim 2, the recombinant vector according to claim 3 or the recombinant cell according to claim 4, or a combination of at least two of them.

6. A method for preparing the reverse transcriptase mutant according to claim 1, characterized in that: The method comprises the following steps: (1) inserting the nucleic acid sequence of reverse transcriptase SEQ ID NO.2 into an expression vector to obtain a wild-type recombinant plasmid MMLVwt, and using the recombinant plasmid as a template, performing site-directed mutagenesis on any one of the 524th, 123rd, 259th, or 466th sites of the reverse transcriptase, or a combination of at least two of them; (2) The mutant plasmid obtained in step (1) is transformed into a host bacterium, cultured and purified to obtain the reverse transcriptase mutant.

7. The method for preparing a reverse transcriptase mutant according to claim 6, characterized in that: The expression vector includes pET28a(+).

8. The method for preparing a reverse transcriptase mutant according to claim 6 or 7, characterized in that: The host bacteria include Escherichia coli, Pichia pastoris or Bacillus subtilis.

9. Use of the reverse transcriptase mutant according to claim 1 in a reverse transcription reaction.

10. The use according to claim 9, characterized in that: The reverse transcription reaction includes any one of RT-PCR, RT-qPCR or RT-LAMP.

Citation Information

Patent Citations

  • Reverse transcriptase mutant

    CN112795549A